Navigation Links
Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community-Based Health Organizations
Date:1/21/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... Commitments the Whole Year Through , , WILSONV...spend more time with family. . . play video games?...make changes that would help them lead fuller, hea... commitment to eat healthier, reduce stress or sav...ttest video games of the season. Video game retail...
(Date:1/8/2009)...n from nausea and vomiting , , THURSDAY,...vents the nausea and vomiting that commonly follow...horizon, Japanese researchers report. , Studies...l in Tokyo found that palonosetron was not only as...ron at avoiding the sickening side effects in the ...
(Date:1/8/2009)...swire/ -- TEAC America, Inc. launches its,next ge...r, currently the,fastest thermal dye-sublimation ...e Las Vegas Convention Center, January 8-11, 2009.... 3 TEAC Autoprinter,configurations, TEAC AL-220S,...0S and AL550S, customers can print up to 68 discs ...
(Date:1/8/2009)...stCall/ -- CardioVascular,BioTherapeutics, Inc. (...,additional hospitals in the United States opened...inical trial for the treatment of severe coronary ...ornia Medical Center San Diego, CA,and Holy Cros...spital Fairfield (Ohio) and The Christ Hospital in...
Breaking Medicine News(10 mins):Health News:Video Games Make New Year's Resolutions Easier to Keep 2Health News:Video Games Make New Year's Resolutions Easier to Keep 3Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial 2
...duce their risk of birth defects. Now, new researc...alive.// Researchers say about 31,000 stroke-relat...eaths may have been prevented each year since fort...owers homocysteine levels. People with higher homo...
...dy researchers say the estrogen pills do not reduc...reased risk of stroke.// Researchers say their re...ase or decrease the risk of heart disease as combi.... Estrogen also does not appear to affect a woman’...
...rus could help fight another. Researchers say the ...tis G , may hold a key to helping researchers devi...zed results from the Multicenter Acquired Immunode... investigators followed a large group of HIV-infec...
...hers have found , medication errors that occur in ... than previously thought. Researchers studied mor...atric intensive care units to determine the preval...an error as any preventable event that may cause o...
Other Medicine News:
(Date:1/8/2009)...ose in an ongoing Phase Ib trial demonstrated a 2.... , , Conference Call Today at 8:30AM EST , ,...ys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today a...ng Phase Ib clinical trial of ANA598, the Company,...tor. ANA598 was very well-tolerated and demonstra...
(Date:1/7/2009)...crease , , WHITE PLAINS, N.Y., Jan. 7 /PRNewswi...m that the decades-long rise in the United States ... than ever at increased risk of death and disabili...543,000 babies were born too soon in 2006, accordi...hich today released "Births: Final data for 2006,"...
(Date:1/7/2009)...iantan Puhua Hospital Stem Cells Center ( http://w...sing stem cells to effectively treat neurological ...enced additions to its medical and research staff ... capabilities for growing numbers of incoming inte... the distinguished Dr. Jiang Ping, who was named C...
(Date:1/6/2009)...aintaining a healthy immune system , , PURCHASE...d study in Nutrition and Cancer (60(5), 643-651)...aka, Japan has shown that AHCC (Active Hexose Corr...asing the number of dendritic cells (DCs). DCs are...resenting foreign substances to other immune syste...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Preterm Births Rise 36 Percent Since Early 1980s 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 1Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 2Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 3Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 4Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 5Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 6Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 7Abbotts Kaletra 28R 29 Tablet Dosed Once Daily or Twice Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2786 8New decision model seeks to avert flu vaccine mismatch of 2007 2008 season 25013 1New decision model seeks to avert flu vaccine mismatch of 2007 2008 season 25013 2ICS presents prestigious Digby McLaren Medal to Cincinnatis Carl Brett 4342 1ICS presents prestigious Digby McLaren Medal to Cincinnatis Carl Brett 4342 2ICS presents prestigious Digby McLaren Medal to Cincinnatis Carl Brett 4342 3Nurturing Parents Can Cut Risk of Aggression in Girls 25012 1Nurturing Parents Can Cut Risk of Aggression in Girls 25012 2
...ighlight VELCADE efficacy in broad range,of patien...s., June 19, 2007 /PRNewswire-FirstCall/ --,Millen...ta for,VELCADE, the market leading therapy with un...previously treated multiple myeloma,(MM), will be ...kshop (IMW) in Kos, Greece, June 25-30, 2007. , "C...
... Endpoint of Improvement in Overall,Survival, WEST...l/ --,Allos Therapeutics, Inc. today announced top...hase 3 study of Efaproxyn ,(efaproxiral) plus whol...in metastases originating from breast cancer. The ...monstrating a,statistically significant improvemen...
Other Medicine Technology:Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6
...Comfort Pick one of our pipettors up and use it. ... positionsright where they should beeven if youre ...omically designed to help avoid repetitive stress ...ctivity In The Palm Of Your Hand Start dispensing...
...st value in high performance electronic pipetting!...t design reduce hand fatigue and strain , Stress-f...lor coding for easy volume identification , Accept...milton AdvanTip Low Retention and AdvanTip Precisi...
The Finnpipette BioControl multichannel has the same innovative features as the single channel model.The same universal handle fits allseven multichannel and five single channel tip cone modules. Bot
... is ideal for all liquid handling applications in ...mically-placed operating buttons, and various disp...everse pipetting and diluting make this a lab favo...of a manual pipette without any adverse effects on...
Medicine Products: